PIK-75 hydrochloride
Code | Size | Price |
---|
TAR-T2287-5mg | 5mg | £102.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2287-10mg | 10mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2287-1mL | 1 mL * 10 mM (in DMSO) | £124.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2287-25mg | 25mg | £132.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2287-50mg | 50mg | £172.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2287-100mg | 100mg | £213.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
PIK-75 Hydrochloride is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM in cell-free assays.
CAS:
372196-77-5
Formula:
C16H15BrClN5O4S
Molecular Weight:
488.74
Pathway:
DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling; Apoptosis
Purity:
0.98
SMILES:
Cl.CN(N=Cc1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O
Target:
Apoptosis; DNA-PK; PI3K
References
1. Zheng Z, et al. Mol Pharmacol. 2011, 80(4), 657-664.
2. WO/2003/072557, 09/04/2003
3. Moir LM, et al. J Pharmacol Exp Ther. 2011, 337(2), 557-566.
4. Jude JA, et al. Am J Respir Cell Mol Biol. 2012. doi:10.1165/rcmb.2012-0025OC.
5. Smirnova T, et al. Oncogene. 2012, 31(6), 706-715.